Cargando…

Targeting gastrointestinal stromal tumors: the role of regorafenib

Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schroeder, Brett, Li, Zula, Cranmer, Lee D, Jones, Robin L, Pollack, Seth M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881930/ https://www.ncbi.nlm.nih.gov/pubmed/27284251 http://dx.doi.org/10.2147/OTT.S104081

Ejemplares similares

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1 That Was Successfully Treated with Regorafenib
por: Fujimi, Akihito, et al.
Publicado: (2019)

Multiple Liver Abscess Formation and Primary Gastrointestinal Stromal Tumor
por: E. Chang, Amy, et al.
Publicado: (2013)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
por: Schvartsman, Gustavo, et al.
Publicado: (2017)

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
por: Kollàr, Attila, et al.
Publicado: (2014)

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study
por: Nannini, M., et al.
Publicado: (2021)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
por: Nannini, Margherita, et al.
Publicado: (2017)

Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists
por: Rey, Jean-Baptiste, et al.
Publicado: (2014)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Gastrointestinal stromal tumor and its targeted therapeutics
por: Dupart, Jheri, et al.
Publicado: (2011)

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
por: Fondevila, Flavia, et al.
Publicado: (2019)

Gastrointestinal stromal tumor
por: Stamatakos, Michael, et al.
Publicado: (2009)

Gastrointestinal stromal tumors
por: Beham, Alexander W., et al.
Publicado: (2011)

Recent advances in the systemic treatment of gastrointestinal stromal tumors
por: Jones, Robin L., et al.
Publicado: (2023)

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
por: Yeh, Chun-Nan, et al.
Publicado: (2017)

Practical Aspects of Risk Assessment in Gastrointestinal Stromal Tumors
por: Jones, R. L.
Publicado: (2014)

Gastrointestinal Stromal Tumors: Molecular Mechanisms and Targeted Therapies
por: Downs-Kelly, Erinn, et al.
Publicado: (2011)

Syndromic gastrointestinal stromal tumors
por: Ricci, Riccardo
Publicado: (2016)

Pathology of Gastrointestinal Stromal Tumors
por: Foo, Wai Chin, et al.
Publicado: (2012)

Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report
por: KUWAYAMA, MIYUKI, et al.
Publicado: (2016)

Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial
por: Jeffers, Michael, et al.
Publicado: (2022)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
por: Zhao, Yue, et al.
Publicado: (2020)

The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
por: Astolfi, Annalisa, et al.
Publicado: (2020)

Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
por: Golčić, Marin, et al.
Publicado: (2023)

Radiotherapy for Gastrointestinal Stromal Tumors
por: Ozkan, Emine Elif
Publicado: (2018)

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
por: Son, Myoung Kyun, et al.
Publicado: (2017)

Immunotherapy Strategies for Gastrointestinal Stromal Tumor
por: Arshad, Junaid, et al.
Publicado: (2021)

Somatic pharmacogenomics of gastrointestinal stromal tumor
por: Ravegnini, Gloria, et al.
Publicado: (2019)

Precision Oncology in Gastrointestinal Stromal Tumors
por: Mechahougui, Hiba, et al.
Publicado: (2023)

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre
por: Chamberlain, Florence, et al.
Publicado: (2020)

Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study
por: Yeh, Chun-Nan, et al.
Publicado: (2021)

Imaging spectrum of gastrointestinal stromal tumor
por: Sureka, Binit, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c7q9c15mp27lddh49o28amdabv